AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Twist Bioscience Teams Up with Synthetic Design Lab for Novel Therapeutic Development
ByAinvest
Tuesday, Sep 2, 2025 8:04 am ET1min read
Twist Bioscience has collaborated with Synthetic Design Lab to support the development of novel antibody-drug conjugates for cancer treatment. Twist will leverage its high throughput services and expertise in antibody engineering to advance Synthetic Design Lab's mission to unlock the full potential of its SYNTHBODY platform. The collaboration aims to accelerate the discovery and development of novel therapeutics.
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, has entered into a collaboration with Synthetic Design Lab (SDL), a next-generation therapeutics company, to support the development of novel antibody-drug conjugates (ADCs) for various cancer types. The collaboration leverages Twist Bioscience's high throughput expertise in novel binder discovery services and high throughput screening capabilities to accelerate Synthetic Design Lab's mission to unlock the full potential of its SYNTHBODY platform [1].Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, commented on the collaboration, stating, "With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics. We are uniquely positioned to support Synthetic Design Lab’s development of novel antibody-drug conjugates for various cancer types" [1].
Daniel S. Chen, M.D., Ph.D., Chief Executive Officer of Synthetic Design Lab, expressed his enthusiasm for the collaboration, stating, "Collaborating with Twist, we’re able to leverage their extensive suite of high throughput services to help us advance on our mission to unlock the full potential of our proprietary approach. We believe that with our SYNTHBODY platform, we can develop a broad suite of therapeutics that are far more advanced than what is available today" [1].
Twist Bioscience will utilize its proprietary tools and platform to conduct specific research activities, supporting Synthetic Design Lab's efforts. The collaboration aims to accelerate the discovery and development of novel therapeutics, potentially offering significant advancements in cancer treatment [1].
References:
[1] https://www.stocktitan.net/news/TWST/twist-bioscience-collaborates-with-synthetic-design-6kxplpcsob7n.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet